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Abstract
Background: Transapical approach (TA) is an established access alternative to the transfemoral technique in
patients undergoing transcatheter aortic valve replacement (TAVR) for treatment of symptomatic aortic valve
stenosis. The impact of prior coronary artery bypass grafting (CABG) on clinical outcomes in patients undergoing
TA-TAVR is not well defined.
Methods: A single center retrospective cohort analysis of 126 patients (male 41%, mean age 85.8 ± 6.1 years) who
underwent TA balloon expandable TAVR (Edwards SAPIEN, SAPIEN XT or SAPIEN 3) was performed. Patients were
classified as having prior CABG (n = 45) or no prior CABG (n = 81). Baseline clinical characteristics, in-hospital, 30-day,
6 months and one-year clinical outcomes were compared.
Results: Compared to patients without prior CABG, CABG patients were more likely to be male (62.2 vs. 29.6%, p < 0.001)
with a higher STS score (11.66 ± 5.47 vs. 8.99 ± 4.19, p = 0.003), history of myocardial infarction (55 vs. 21.1%, p< 0.001),
implantable cardioverter defibrillator (17.8 vs. 3.7%, p = 0.017), left main coronary artery disease (42.2 vs. 4.9%, p < 0.001),
and proximal left anterior descending coronary artery stenosis (57.8 vs. 16%, p < 0.001). They also presented with a lower
left ventricular ejection fraction (%) (42.3 ± 15.3 vs. 54.3 ± 11.6, p < 0.01) and a larger effective valve orifice area (0.75 ± 0.
20 cm2 vs. 0.67 ± 0.14 cm2, p = 0.025). There were no intra-procedural deaths, no differences in stroke (0 vs. 1.2%, p = 1.0),
procedure time in hours (3.50 ± 0.80 vs. 3.26 ± 0.86, p = 0.127), re-intubation rate (8.9 vs. 8.6% p = 1.0), and renal function
(highest creatinine value 1.73 ± 0.71 mg/ml vs.1.88 ± 1.15 mg/ml, p = 0.43). All-cause mortality at 6 months was similar in
both groups (11.4, vs. 17.3% p = 0.44), and one-year survival was 81.8 and 77.8% respectively (p = 0.51). On multivariate
analysis, the only factor significantly associated with one-year mortality was prior history of stroke (HR, 2.76; 95% CI, 1.06-7.
17, p = 0.037).
Conclusion: Despite the higher baseline clinical risk profile, patients with history of prior CABG undergoing TA-TAVR had
comparable in-hospital, 6 months and one-year clinical outcomes to those without prior CABG.
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Background
Redo cardiac surgery is associated with an increased risk
of morbidity and mortality in comparison with an initial
cardiac operation [1–3]. In patients with prior coronary
artery bypass grafting (CABG) and patent grafts under-
going reoperation for surgical aortic valve replacement
(SAVR), in addition to technical issues related to cicatrix
formation and dissection, myocardial protection and
prevention of graft injuries are concerns that require
careful surgical management [3, 4].
Transcatheter aortic valve replacement (TAVR) has
shown good early and mid-term results in patients with
severe aortic stenosis and various comorbidities or inop-
erable patients [5–7]. High-risk or inoperable patients
with severe aortic stenosis who had previously under-
gone cardiac surgery represent a particularly challenging
group that could benefit from a minimally invasive
trans-catheter approach. Trans-apical (TA) TAVR has
become an alternative access site for the treatment of
high-risk patients with severe symptomatic aortic sten-
osis. Because of the minimally invasive nature of this ap-
proach, TA-TAVR has become particularly attractive in
high-risk patients with prior cardiac surgery [8, 9]. How-
ever up to now the impact of prior CABG on the clinical
outcome after TA-TAVR has yet to be defined. The pur-
pose of the present study was to compare outcomes of
patients with prior CABG undergoing TA-TAVR with
those undergoing TA-TAVR as an initial procedure.
Methods
Patients
Between October 2010 and December 2014, 126 con-
secutive high-risk patients (male 41%, mean age 85.8 ±
6.1) underwent TA-TAVR. Of these, 45 patients (36%)
have had prior CABG. Patients included in the study
were symptomatic adults (94% had NYHA class III and
IV) with severe aortic stenosis who were not candidates
for SAVR because of co-morbidities. Severe aortic sten-
osis was defined by effective valve orifice area <0.8 cm2,
mean aortic valve gradient ≥40 mmHg, or peak aortic jet
velocity ≥4.0 m per second. Risk factors for cardiovascu-
lar surgery were assessed on the Society for Thoracic
Surgeons (STS) calculator (STS score >10% indicating
very high surgical risk). Patient data were collected pro-
spectively during treatment using standardized forms to
record demographic and clinical characteristics as well
as procedural data. Pre-interventional patient screening
included trans-thoracic echocardiography and coronary
artery angiography for exclusion of coronary artery dis-
ease. For patients identified with coronary artery disease,
a revascularization procedure was performed prior to
the valve replacement. Aortic and mitral regurgitation
were assessed in all relevant views using color and spec-
tral Doppler. Transvalvular regurgitation was graded
according to American Society of Echocardiography rec-
ommendations as none, trace, mild, moderate, or severe.
Follow-up was obtained at 30 days, 6 months and one
year based on the medical records and on physician and
patient interviews. All patients had trans-thoracic echo-
cardiography at 30 days and one-year clinical follow-up.
The primary end-point of this analysis was death from
any cause at 6 months and one year. Secondary safety
end-points were major adverse events as defined by the
Society for Thoracic Surgeons and the American College of
Cardiology TVT Registry™ (https://www.ncdr.com/
WebNCDR/docs/default-source/tvt-public-page-document
s/tvt-registry-2_0_coderdatadictionary.pdf?sfvrsn=2) and
Valve Academic Research Consortium (VARC) [10] criteria.
The therapeutic options of SAVR (with CABG where ap-
plicable) or TA-TAVR were discussed extensively with all
patients. The choice of treatment was made at the discre-
tion of the heart team, consisting of cardiac surgeons and
interventional cardiologists, based on individual risk assess-
ment, patient preference and a transfemoral-first evaluation
process. The study protocol was approved by the institu-
tional review board at the medical school and individual pa-
tient consent was obtained.
Aortic valve implantation
Procedural details of the technique have been previously
described [11]. All operations were performed in a spe-
cially equipped angiography suite that fulfills the stan-
dards of a hybrid operating room. Besides standard
hemodynamic monitoring, transesophageal echocardiog-
raphy was routinely utilized and cardiopulmonary bypass
was available in all cases.
A transverse incision approximately 8 cm in length was
created in the inframammary position. This was carried
through subcutaneous tissues using Bovie electrocautery. A
retractor was placed and pleural adhesions were carefully
dissected free. The pericardium was identified and carefully
opened. Adhesions of the heart to the pericardial cavity
were carefully dissected. An area approximately 2 cm su-
perior and 2 cm lateral to the true apex was identified. Cir-
cumferential pursestring sutures were placed using 2–0
Prolene suture. Heparin was given to achieve an ACT of
greater than 250 s. The apex was accessed with a needle
and through the use of a Supra Core wire (Abbott Vascular,
Santa Clara, CA, USA) the aortic valve was crossed. The
commercially available balloon-expandable aortic valve
prosthesis Edwards SAPIEN™, SAPIEN XT™ or SAPIEN 3™
was used (Edwards Lifesciences, Irvine, CA, USA). Fluoros-
copy and trans-esophageal echocardiography were used to
guide the catheter across the native valve and direct deploy-
ment of the stent at the level of the annulus. During a
period of rapid pacing, the valve was deployed. Valve func-
tion was immediately assessed by angiographic and echo-
cardiographic visualization. Pursestring sutures were tied
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and a buttressing 3–0 Prolene pledgeted suture was placed
in a mattress fashion. A left lateral chest tube was inserted.
The incision was closed in a standard fashion and sterile
dressings were applied.
Statistical analysis
Data are presented as frequency distributions and percent-
ages. All continuous data are expressed as mean ± stand-
ard deviation and categorical data are reported as count
(percent). Categorical variables were analyzed with the
Fischer’s exact test or X2 test and continuous variables
with Student’s t-tests for means with normal distribution,
and the Wilcoxon rank sum test for skewed data. Time-
to-event data were summarized by frequencies and log-
rank statistics. For one-year survival, Kaplan-Meier
estimates were calculated and compared using the log-
rank test. A univariate Cox model was used to analyze
one-year survival data, with a P value of less than 0.10 in-
dicating statistical significance. A multivariate Cox model
with stepwise regression, adjusted for history of stroke,
dyslipidemia, presence of pre-procedure atrial fibrillation,
STS score, NYHA class, severity of pre-procedure aortic
regurgitation and new onset atrial fibrillation was used to
assess hazard ratios (HR) and 95% confidence interval
(CI). A P-value of 0.05 indicated statistical significance. All
statistics were computed with the SPSS software (SPSS
21.0 for Windows, SPSS Inc).
Results
Patient characteristics and co-morbidities
One hundred and twenty-six consecutive patients under-
went TA-TAVR at our institution during the study
period; 45 (36%) had a prior history of CABG. Table 1
summarizes the preoperative characteristics of this co-
hort. Compared to patients without prior CABG, CABG
patients were more likely to be male (62,2 vs. 29.6%, p <
0.001), with higher prevalence of dyslipidemia (88.9 vs.
72.8%, p = 0.04) and diabetes (44.4 vs. 23.5%, p = 0.02),
history of myocardial infarction (55 vs. 21.1%, p < 0.001),
implantable cardioverter defibrillator (17.8 vs. 3.7%, p =
0.017), left main coronary artery disease (42.2 vs. 4.9%,
p < 0.001) and proximal left anterior descending coron-
ary artery stenosis (57.8 vs. 16%, p < 0.001). The mean
calculated STS score was higher in the CABG group
(11.66 ± 5.47 vs. 8.99 ± 4.19, p = 0.003). Echocardiog-
raphy before valve implantation showed significantly
lower left ventricular ejection fraction (%) (42.3 ± 15.3
vs. 54.3 ± 11.6, p < 0.01), a slightly larger effective
valve orifice area (0.75 ± 0.20 cm2 vs. 0.67 ± 0.14 cm2,
p = 0.025), a larger left ventricular diameter at end
systole (4.05 ± 1.88 cm vs. 3.42 ± 1.21 cm, p = 0.026)
and a higher prevalence of moderate/severe mitral
valve regurgitation (16.0 vs. 35.6%, p = 0.016) in
patients with prior CABG.
Procedural data and in-hospital outcomes
Procedural data for the study cohort are shown in
Table 2. All patients received a balloon-expandable
Edwards SAPIEN™, Edwards SAPIEN XT™ or Edwards
SAPIEN 3™ aortic valve prosthesis; a 23 mm bioprosth-
esis was more frequently used in the non CABG group
(66.3 vs. 35.6%), whereas a 26 mm bioprosthesis was
more frequently used in the CABG group (62.2 vs.
32.5%) (p = 0.002). Mean surgical time in hours was
slightly higher, but not significantly different, in prior
CABG patients (3.50 ± 0.80 vs. 3.26 ± 0.86, p = 0.127).
There were no conversions to open heart surgery, no
aborted procedures, and no intra-operative deaths. In
two patients with prior CABG cardiopulmonary bypass
through femoro-femoral cannulation was used for per-
sistent hypotension (4.4% vs. 0, p = 0.126). In-hospital
length of stay, stroke, myocardial infarction, duration of
intubation, re-intubation, renal function after the pro-
cedure, conduction abnormalities (new left bundle
brunch block or right bundle brunch block) and VARC
defined bleeding and vascular complications were similar
between the two groups. Post-procedure new onset atrial
fibrillation was significantly lower in the CABG group
(11.1 vs. 30.9%, p = 0.016). Permanent pacemaker im-
plantation was required in 4.9% of patients without and
6.7%, with prior CABG (p = 0.7).
One-year clinical outcomes
All but one patients had clinical follow up at 6 months
and one year. All-cause mortality at six months (11.4 vs.
17.3%, p = 0.44) and one year (18.2 vs. 22.2%, p = 0.65)
were similar in patients with and without prior CABG.
Similar results were observed with cardiovascular mor-
tality (Table 3). Survival at one year was 81.8% for pa-
tients with and 77.8% for patients without prior CABG
(p = 0.51) (Fig. 1). Improvements in echocardiographic
parameters were marked and sustained both at 30 days
and at one-year relative to pre-procedure values
(Table 4). There were no cases of recurrent aortic sten-
osis or moderate/severe aortic insufficiency in either
group of patients. At 30 days, the effective aortic valve
area was 1.64 ± 0.25 cm2 and 1.62 ± 0.31 cm2 (p = 0.66)
in patients with and without prior CABG and mean gra-
dient was 9.7 ± 3.3 mm Hg and 10.2 ± 3.9 mm Hg (p =
0.54) respectively; at one-year effective aortic valve area
was 1.82 ± 0.35 cm2 and 1.66 ± 0.40 cm2 (p = 0.08) with a
mean gradient of 10.0 ± 4.0 mm Hg and 11.6 ± 6.4 mm
Hg (p = 0.23) respectively. Patients with prior CABG
maintained a lower left ventricular ejection fraction
(47.2% ± 14.3% vs. 57.1% ± 9.6%, p < 0.001 and 43.9% ±
16.1%, vs. 60.0% ± 8.1% p < 0.001) at 30 days and one
year respectively; however, the changes (Δ) on left ven-
tricular ejection fraction pre and post procedure (at
30 days and one year) were not statistically different in
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both groups of patients. Post-operative incidence of
moderate/severe mitral valve regurgitation was compar-
able between the two groups at 30 days and one-year
(12.2 vs 20.0%, p = 0.295 and 12.5 vs 14.2%, p = 1.0, re-
spectively). On multivariate analysis, the only factor sig-
nificantly associated with one-year mortality was prior
history of stroke (HR, 2.76; 95% CI, 1.06-7.17, p = 0.037).
Neither prior CABG nor new onset atrial fibrillation
were significantly associated with 1-year mortality (HR,
0.76; 95% CI, 0.33-1.74, p = 0.51 and HR, 1.76; 95% CI,
0.78-3.95, p = 0.17 respectively).
Discussion
This study demonstrates that prior CABG in patients
undergoing TA-TAVR does not impair clinical outcome.
Patients with CABG presented herein had a clearly
Table 1 Baseline characteristics of patients of the Prior Coronary Artery Bypass Graft Surgery and the Initial Transapical Transcatheter
Aortic Valve Replacement Groups
No CABG (N = 81) CABG (N = 45) P Value
Age 85.8 ± 6.1 82.5 ± 7.4 0.008
Male, (%) 24 (29.6) 28 (62.2) <0.001
BMI 25.58 ± 4.84 25.41 ± 4.70 0.853
STS Score 8.99 ± 4.19 11.66 ± 5.47 0.003
NYHA III or IV 56 (69.1) 34 (75.6) 0.539
Permanent PM 9 (11.1) 10 (22.2) 0.120
ICD 3 (3.7) 8 (17.8) 0.017
Atrial Fibrillation 27 (33.3) 20 (44.4) 0.251
Previous MI 16 (21.1) 22 (55) <0.001
Prior PCI 41 (50.6) 20 (44.4) 0.578
Stroke 8 (9.9) 7 (15.6) 0.395
Transient Ischemic Attack 6 (7.4) 6 (13.3) 0.346
PAD 25 (30.9) 20 (44.4) 0.174
Smoking History 52 (64.2) 30 (66.7) 0.847
Hypertension 69 (85.2) 42 (93.3) 0.253
Dyslipidemia 59 (72.8) 40 (88.9) 0.042
Diabetes 19 (23.5) 20 (44.4) 0.017
Oral Medications only 9 (11.1) 11 (24.4) 0.073
Insulin only 5 (6.2) 5 (11.1) 0.328
Immunocompromise Present 12 (14.8) 1 (2.2) 0.031
Left Main Stenosis > 50% 4 (4.9) 19 (42.2) <0.001
Proximal LAD > 70% stenosis 13 (16.0) 26 (57.8) <0.001
Renal Dialysis 3 (3.7) 1 (2.2) 1.0
Creatinine mg/dl 1.28 ± 0.65 1.32 ± 0.48 0.686
Echocardiography
Aortic Valve Area, cm2 0.67 ± 0.14 0.75 ± 0.20 0.025
LVEF (%) 54.3 ± 11.6 42.3 ± 15.3 <0.001
Aortic Valve Mean Gradient, mm Hg 47.7 ± 12.5 44.1 ± 11.9 0.126
Aortic Valve Peak Gradient, mm Hg 82.5 ± 22.4 75.8 ± 18.6 0.091
Aortic Valve Regurgitation Moderate/Severe 1 (1.2) 1 (2.2) 1.0
Mitral Valve Regurgitation Moderate/Severe 13 (16.0) 16 (35.6) 0.016
LVIDs, cm 3.42 ± 1.21 4.05 ± 1.88 0.026
LVIDd, cm 4.96 ± 1.14 5.30 ± 1.91 0.212
Results are number (%) or mean ± standard deviation
CABG Coronary artery bypass graft, BMI Body mass index, NYHA New York Heart Association classification, STS Society of Thoracic Surgeons, PM Pacemaker, ICD
Implantable cardioverter defibrillator, MI Myocardial infarction, PCI Percutaneous coronary intervention, PAD Peripheral arterial disease, LAD Left anterior
descending, LVEF Left ventricular ejection fraction, LVIDs Left ventricular diameter at end systole, LVIDd Left ventricular diameter at end diastole
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elevated risk profile as expressed by a higher STS risk
score, an increased prevalence of dyslipidemia, diabetes,
previous myocardial infarction and significant left main
stenosis, and a lower left ventricular ejection fraction.
Despite the high risk profile, procedural aspects, post-
procedural complication rates, and one-year clinical
outcome, were comparable between the two groups;
one-year survival was 81.8 and 77.8% for patients with
Table 2 Procedural characteristics and in-hospital outcomes
No CABG (n = 81) CABG (n = 45) p Value
Procedural Data
Valve size
23 53 (66.3) 16 (35.6) 0.002
26 26 (32.5) 28 (62.2)
29 1 (1.3) 1 (2.2)
Procedure Time (Hours) 3.26 ± 0.86 3.50 ± 0.80 0.127
Cardiopulmonary Bypass 0 2 (4.4) 0.126
Outcomes
Stroke 1 (1.2) 0 1.0
MI 0 0
New Renal Failure requiring Hemodialysis 5 (6.2) 1 (2.2) 0.420
Respiratory Distress 19 (23.5) 12 (26.7) 0.829
Re-Intubation 7 (8.6) 4 (8.9) 1.0
Coronary Obstruction 0 0
In Hospital Creatinine, (highest value, mg/dl) 1.88 ± 1.15 1.73 ± 0.71 0.430
Creatinine at discharge (mg/dl) 1.33 ± 0.67 (N = 76) 1.40 ± 0.57 0.560
Hospitalization Duration 10.48 ± 6.7 9.64 ± 7.9 0.531
Arrhythmias
Conduction Disturbance 12 (14.8) 6 (13.3) 1.0
New LBBB 10 (12.3) 6 (13.3) 1.0
New RBBB 2 (2.5) 0 0.537
New Atrial Fibrillation 25 (30.9) 5 (11.1) 0.016
New Other Significant Arrhythmia 13 (16.0) 5 (11.1) 0.597
Permanent Pacemaker Implantation 4 (4.9) 3 (6.7) 0.700
Bleeding
Life Threatening Bleedinga 4 (4.9) 1 (2.2) 0.654
Major Bleedinga 28 (34.6) 15 (33.3) 1.0
Gastrointestinal Bleeding 4 (4.9) 0 0.296
Genitourinary Bleeding 4 (4.9) 3 (6.7) 0.700
Transapical approach related 4 (4.9) 2 (4.4) 1.0
PRBC Transfusion 48 (59.3) 29 (64.4) 0.703
# Units transfused 2.2 ± 2.0 2.1 ± 1.4 0.947
Vascular Complications
Major Vascular Complication 1 (1.2) 0 1.0
Minor Vascular Complication 1 (1.2) 0 1.0
Annular Dissection 0 0
Requirement of CT surgery 0 2 (4.4) 0.126
Requirement of Vascular Surgery 0 0
Results are number (%) or mean ± standard deviation
MI Myocardial infarction, LBBB Left bundle branch block, RBBB Right bundle branch block, PRBC Packed red blood cells, CT Cardiothoracic surgery
aDefined using VARC criteria10
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and without prior CABG respectively (p = 0.509). Inter-
estingly, patients with prior CABG exhibited a smaller
incidence of new onset atrial fibrillation (p = 0.016).
However, on multivariate analysis new onset atrial fibril-
lation did not significantly increase the hazard for one-
year mortality. Conduction abnormalities and permanent
pacemaker placement rate were comparable between the
two groups. Echocardiography measurements of the aor-
tic valve were similar both at 30 days and at one year
and changes on left ventricular ejection fraction at fol-
low up were not statistically different in both groups of
patients. The only predictor for mortality on multivariate
analysis was history of stroke.
TAVR has been documented to be safe and effective in
inoperable patients with severe aortic stenosis and has
also emerged as an alternative to open SAVR in high-
risk patients with severe aortic stenosis [5, 6]. Patients
undergoing cardiac re-operation consist a high-risk sub-
group [12]. Despite previous reports showing that SAVR
can be performed safely and with excellent outcomes in
patients with prior CABG [13, 14], the risk of mortality
and morbidity in this subgroup is higher. Repeat sternot-
omy pose the risk of coronary graft injury during re-
entry to the mediastinum and difficulty in myocardial
protection as well as potential traumatic injury and
hemorrhage [3, 12]. Moreover, multiple co-morbidities
render this population as a surgically challenging group.
Thus, TAVR has been suggested as a viable option in
these patients. The proportion of TAVR patients with
prior CABG has been reported to range from 25.5 to
42% [15]. TAVR patients with a history of prior cardiac
surgery have documented to be younger and have more
co-morbidities, such as diabetes, porcelain aorta, periph-
eral vascular disease and poor left ventricular ejection
fraction compared with patients without previous car-
diac operation [2, 15].
Several studies have shown the feasibility of TAVR in
patients with prior CABG regardless of the access site.
On multivariate analysis of PARTNER I trial, where
high-risk patients with severe aortic stenosis were ran-
domized to SAVR or TAVR, prior CABG was shown to
have no impact on prognosis after TAVR [16]. In a sub-
group analysis of the same trial no differences between
patients with previous cardiac operation following TAVR
vs SAVR in terms of operative outcomes were found;
Table 3 Mortality at clinical follow-up
No CABG (n = 81) CABG (n = 44) p Value
At 6 months
All-Cause Mortality 14 (17.3) 5 (11.4) 0.444
Cardiovascular Mortality 5 (6.2) 2 (4.5)
At 1 year
All-Cause Mortality 18 (22.2) 8 (18.2) 0.651
Cardiovascular Mortality 7 (8.6) 3 (6.8)
Data expressed as n (%)
Fig. 1 Time-to-event curves for cumulative survival. Events were calculated with the use of Kaplan-Meier methods. (Previous CABG: green line; No
CABG: blue line) p = 0.509
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however, a trend towards greater all-cause mortality was
seen in the TAVR group at 2 years [17]. Similarly, in a
recent report from the European SOURCE XT registry,
which included 2.688 patients who underwent TAVR
with the SAPIEN XT valve, prior CABG was not associ-
ated with one year mortality [18]. These findings are in
accordance with data from FRANCE 2 Registry in which
30-day and one-year mortality from all causes did not
differ according to history of CABG [19]. Moreover,
there were no significant differences in VARC complica-
tions (myocardial infarction, stroke or vascular and
bleeding complications). On multivariate analysis, CABG
was not associated with greater one year post-TAVR
mortality. In their study of 201 patients, 140 (70%) of
whom underwent TAVR through trans-arterial approach
and 61 patients through TA approach, Ducrocq et al. re-
ported similar mortality rates in TAVR patients irre-
spective of prior CABG history and concluded that
TAVR is an attractive option in high risk population
with symptomatic severe aortic stenosis and previous
heart surgery [8].
Currently, only a few studies have reported on progno-
sis after TA-TAVR in relation to prior CABG and the
exact impact of previous cardiac operation on mortality
after TA-TAVR is not well established. In a retrospective
study of 566 patients, 110 (19.4%) with a history of prior
CABG, who underwent TA-TAVR from the Italian
Registry all-cause and cardiovascular mortality at 30 days
and survival at one and two years were similar between
patients with and without prior CABG [2]. Additionally,
there were no significant differences between the two
groups in terms of post-procedure complications. In line
with the above study, no differences in the short-term
and long-term mortality were documented between
propensity-matched subgroups of 45 TAVR patients with
and 45 TAVR patients without prior CABG in a study
by Papadopoulos et al. [20]. Echocardiography at 4 years
showed no differences in left ventricular ejection frac-
tion, effective orifice valve area and mean trans-valvular
gradient between the two groups in this study. The find-
ings of the above studies were also comparable with re-
ports by Drews et al. [21], and Walther et al. [22] and
Table 4 Echocardiographic results at clinical follow-up
No CABG (n = 75) CABG (n = 45) p Value
At 30 Days
Aortic Valve Area, cm2 1.62 ± 0.31 1.64 ± 0.25 0.655
LVEF, % 57.1 ± 9.6 47.2 ± 14.3 <0.001
Aortic Valve Mean Gradient, mm Hg 10.2 ± 3.9 9.7 ± 3.3 0.534
Aortic Valve Peak Gradient, mm Hg 20.1 ± 7.0 19.9 ± 6.9 0.923
LVIDs, cm 3.59 ± 0.66 4.30 ± 1.0 <0.001
LVIDd, cm 5.13 ± 0.64 5.64 ± 0.82 <0.001
Δ LVEF, % 2.6 ± 9.6 3.6 ± 7.7 0.560
Δ LVIDs, cm −0.06 ± 0.51 −0.27 ± 0.46 0.028
Δ LVIDd, cm 0.02 ± 0.52 −0.15 ± 0.61 0.119
AV Regurgitation Moderate/Severe 0 0
MV Regurgitation Moderate/Severe 9 (12.2) 9 (20.0) 0.295
At One Year No CABG (n = 48) CABG (n = 28)
Aortic Valve Area, cm2 1.66 ± 0.40 1.82 ± 0.35 0.079
LVEF, % 60.0 ± 8.1 43.9 ± 16.1 <0.001
Aortic Valve Mean Gradient, mm Hg 11.6 ± 6.4 10.0 ± 4.0 0.234
Aortic Valve Peak Gradient, mm Hg 22.8 ± 12.3 19.0 ± 5.9 0.137
LVIDs 3.39 ± 0.46 4.55 ± 1.37 <0.001
LVIDd, cm 5.02 ± 0.49 5.80 ± 1.09 <0.001
Δ LVEF, % 3.5 ± 7.9 4.9 ± 7.7 0.470
Δ LVIDs, cm −0.21 ± 0.55 −0.18 ± 0.63 0.868
Δ LVIDd, cm −0.07 ± 0.54 −0.02 ± 0.66 0.758
AV Regurgitation Moderate/Severe 0 0
MV Regurgitation Moderate/Severe 6 (12.5) 4 (14.2) 1.0
LV EF Left ventricular ejection fraction, LVIDs Left ventricular diameter at end systole, LVIDd Left ventricular diameter at end diastole. Δ calculated from baseline
pre procedure measurements, AV Aortic valve, MV Mitral valve
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indicate that prior CABG does not have a significant im-
pact morbidity and mortality in patients undergoing TA-
TAVR.
Our results are in accordance with the existing lit-
erature. Mortality at six months and one year follow
up were similar between the two groups, while echo-
cardiography data at 30 days and one year with re-
spect to aortic valve orifice, and trans-valvular
gradient were not different. Moderate/severe mitral
valve regurgitation frequency at 30 days and one-year
after valve implantation was similar between the two
groups and improved from the pre procedure one.
Toggweiler et al. in their study on patients with mod-
erate and severe mitral valve regurgitation had previ-
ously reported an improvement in mitral regurgitation
in 55% of patients with moderate or severe MR after
TAVR at one-year follow up [23]. Additionally, a
lower incidence of new onset atrial fibrillation was
observed post-procedure in patients with prior CABG
(11.1 vs. 30.9%, p = 0.016). Higher prevalence of per-
manent pacemaker and implantable cardioverter de-
fibrillator observed preoperatively in the CABG
population could account for this finding. Yet, when
adjusted for presence of permanent pacemaker and
implantable cardioverter defibrillator, incidence of
atrial fibrillation remained significantly higher in the
non CABG population (p = 0.024). Furthermore, on
multivariate analysis new onset atrial fibrillation was
not predictor for all-cause mortality at one year. Car-
diac surgery has been shown to increase susceptibility
to atrial fibrillation in previous studies [24, 25]. In
our study the prevalence of pre procedure atrial fibril-
lation was not statistically different in patients with
prior CABG (44.4 vs. 33.3%, p = 0.251). The deleteri-
ous impact of atrial fibrillation on TAVR patients was
recently underscored in a sub-analysis from PART-
NER trial [26]. Patients who converted from sinus
rhythm to atrial fibrillation by discharge had the high-
est rates of all-cause mortality at 30 days (adjusted
HR = 3.41; p = 0.0002) and over 2-fold difference at
1 year (adjusted HR = 2.14; p < 0.0001). The presence
of atrial fibrillation on baseline or discharge ECG was
a predictor of one-year mortality. Similarly, in the
FRANCE 2 Registry pre-existing and new-onset atrial
fibrillation are both associated with higher mortality
and morbidity after TAVR [27]. In another study new
onset atrial fibrillation was detected in 21% of pa-
tients; 50% of all the episodes occurred in the initial
24 h after the procedure [28]. TA approach was ob-
served to an important predictor of new onset atrial
fibrillation and is associated with a prolongation of
intensive care unit and hospital stay. In a recent
meta-analysis of twenty-six studies, 14,078 patients
undergoing TAVR, of whom 33.4% had pre-existing
atrial fibrillation and 17.5% had new onset atrial fib-
rillation, were assessed for early and long-term all-
cause mortality, cardiovascular mortality and cerebro-
vascular events. New onset atrial fibrillation patients
showed similar short- and long-term all-cause mortal-
ity when compared to patients in sinus rhythm,
whereas a non-significant increase in the incidence of
cerebrovascular events was observed at long-term
follow-up [29]. On the same line in another study
new onset atrial fibrillation was not associated with
higher stroke or mortality rates at 30 days or one
year of follow-up [30]. In multivariate analysis, atrial
fibrillation pre-procedure but not new onset atrial fib-
rillation was a significant predictor of mortality
throughout the follow-up period (HR 2.2, p = 0.003 at
30 days, and HR 1.5, p = 0.39, respectively).
From the technical point of view, procedure duration in
hours, life threatening bleeding and units of blood trans-
fused were not different between patients with and with-
out prior CABG supporting the concept that chest reentry
during TA-TAVR does not represent a substantial surgical
challenge. Increased incidence of major bleeding was ob-
served in both groups, a finding related to a combination
of low baseline hemoglobin with modest peri-procedural
blood loss on a high risk population. An identifiable
source of bleeding was present in only a few cases and no
statistical significant difference in the incidence was ob-
served between the two groups. Our results show that ad-
hesions and scar tissue in the apical area were not limiting
factors for chest re-entry through apical access. In fact,
the presence of adhesions may actually prevent myocardial
tissue trauma and hemorrhage after valve implantation
and apical closure, as shown by the lack of peri-operative
myocardial infarction in our study patients. The potential
role of patent grafts on minimizing the consequences of
coronary ostia obstruction by calcium displacement or
debris embolization of the coronary arteries following
prosthetic valve deployment is a possible explanation for
the above findings as well.
Permanent neurologic defects remain a concern in high-
risk patients undergoing cardiac surgery. Stroke rate in our
study, was 1.2% for patients without and 0% for patients
with prior CABG undergoing TA-TAVR and were in ac-
cordance with previously published data after TA-TAVR in
patients with and without prior CABG [8, 9, 31, 32]. Fur-
thermore, history of stroke was the only predictor of one
year mortality on multivariate analysis. This improvement
in the prevalence of stroke certainly represents a powerful
advantage of TA-TAVR in high risk patients.
Limitations
The present study does have some limitations. This is a
retrospective report from a single site and with that
comes unavoidable selection and institutional biases.
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Larger randomized trials are required to document
definitive results. Patients included in the study were
treated with either the first (Edwards SAPIEN™), sec-
ond (Edwards SAPIEN XT™) or third generation
(Edwards SAPIEN 3™) balloon-expandable valve. This
may influence the short-term and long-term clinical
outcome.
Conclusions
TA TAVR in patients with prior CABG appears to be
safe and can be carried out with similar results in terms
of mortality compared with patients undergoing TAVR
as their first cardiac operation. TA-TAVR represents an
alternative treatment option to redo SAVR in this high
risk population. The decision regarding the final treat-
ment approach should be individualized on each single
patient after taking into consideration age, the associated
co-morbidities and the need for revascularization.
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